A recent retrospective cohort study showed that drug-naïve diabetic patients treated with GLP-1RAs had 44% reduced risk of CRC (HR: 0.56, 95% CI: 0.44-0.72) compared to propensity-score matched patients treated with insulin.57 If this association can be ascertained in RCT among both diabetic patients and people with obesity, GLP-1RAs could be a highly effective CPAs in these individuals who are at elevated risk of CRC. This evidence concerns the gene INS and colorectal carcinoma.